Home > Boards > US Listed > Medical - Drugs > Oramed Pharmaceuticals (ORMP)

Oramed is the last oral insulin standing

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
trendmkr Member Profile
 
Followed By 12
Posts 911
Boards Moderated 0
Alias Born 05/29/15
160x600 placeholder
Oramed Patent in Europe to be Granted for Oral Delivery of Proteins PR Newswire (US) - 1/28/2020 7:25:00 AM
Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board PR Newswire (US) - 1/23/2020 8:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/21/2020 2:41:09 PM
Oramed Appoints Dr. Jay Skyler to Scientific Advisory Board PR Newswire (US) - 1/21/2020 7:25:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 1/9/2020 3:58:01 PM
Oramed Pharmaceuticals Issues Letter to Shareholders PR Newswire (US) - 1/9/2020 7:00:00 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 12/11/2019 4:53:43 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/6/2019 6:02:01 AM
Oramed Appoints Dr. Arie Mayer to Board of Directors PR Newswire (US) - 12/5/2019 9:12:00 AM
Oramed to Present a Scientific Poster at International Diabetes Federation Congress PR Newswire (US) - 12/2/2019 8:25:00 AM
Annual Report (10-k) Edgar (US Regulatory) - 11/27/2019 4:28:28 PM
Oramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology PR Newswire (US) - 11/21/2019 8:27:00 AM
Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event PR Newswire (US) - 11/19/2019 8:55:00 AM
Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th PR Newswire (US) - 11/14/2019 7:28:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 7:04:56 AM
Oramed Announces Successful Phase IIb Study of Oral Insulin in Type 2 Diabetes PR Newswire (US) - 11/12/2019 7:00:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 10/23/2019 4:36:39 PM
Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference PR Newswire (US) - 9/18/2019 8:38:00 AM
Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801 PR Newswire (US) - 9/17/2019 8:40:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:09:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:08:27 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:07:48 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/16/2019 6:07:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:07:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/16/2019 6:06:32 PM
trendmkr   Tuesday, 12/27/16 12:01:58 PM
Re: None
Post # of 525 
Oramed is the last oral insulin standing

Novo's rather abrupt departure from the oral insulin scene has left Oramed Pharmaceuticals Inc. (ORMP) shareholders caught between confused excitement and mild panic. This is also understandable. On the one hand, Novo's exit gives Oramed easier access to diabetes markets if its own oral insulin candidate ORMD-0801 succeeds. On the other hand, if Novo decided to ax its oral insulin program without even attempting a Phase IIb, doesn't that hint to the entire venture of oral insulin being doomed?

Oramed shares dove over 10% on the news but have been holding in a steady range since then. There are two questions that need to be answered to determine where Oramed goes from here. The first is, why did Novo shutter NN1953? The second is, can Oramed's own ORMD-0801 oral insulin succeed in its own right?

If Novo abandoned NN1953 because it thought the program was a failure, then the implication for Oramed's oral insulin program would be quite negative. If, however, there is an ulterior motive here, then Novo may have just abandoned a multibillion-dollar market to Oramed, assuming ORMD-0801 succeeds and gets approved. But why would Novo do that?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist